Adults with obesity receiving once-weekly semaglutide 7.2 mg lost a higher proportion of their body weight at 72 weeks than ...

Among those who adhered to treatment, the high-dose group achieved an average weight loss of 20.7%, compared to 17.5% with the lower dose and 2.4% in the placebo group. For the overall group ...

The readout comes on the heels of CagriSema’s disappointing Phase III performance, where it missed Novo’s projection of 25% ...

NEW DELHI: Mercedes-Benz unveiled the Concept CLA Class, and Maybach EQS 680 Night Series on Friday at the Bharat Mobility Expo 2025 in Delhi. This concept vehicle marks the electric successor to ...

As demand for weight-loss injections sold under brand names such as Ozempic and Wegovy continues to soar, a study has ...

A novel GLP-1 and amylin receptor agonist featured a safety profile similar to other incretin-based therapies and conferred a ...

Novo Nordisk's high dose Wegovy (semaglutide) has shown improved weight loss while remaining safe and tolerable. In the Phase IIIb STEP UP trial, 7.2mg Wegovy demonstrated statistically ...

If you're one of the 13% of American adults who has taken a GLP-1 drug for weight loss, you may know that while fat seemingly ...

Novo Nordisk said that patients taking a higher dose of its blockbuster Wegovy obesity shot lost more weight than those on a lower dose without experiencing an increase in side effects ...

The White House on Friday said Novo Nordisk’s weight-loss drugs Wegovy and Ozempic were among the 15 medications picked for a round of price negotiations with Medicare. The companies do not have ...

Our results support the hypothesis that a low initial dose of prednisone is sufficient to control PMR in the majority of patients. They also suggest that 0.20 mg per kg weight could be the ...